0000880771-17-000120.txt : 20170703
0000880771-17-000120.hdr.sgml : 20170703
20170703160217
ACCESSION NUMBER: 0000880771-17-000120
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170630
FILED AS OF DATE: 20170703
DATE AS OF CHANGE: 20170703
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SCICLONE PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000880771
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943116852
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 950 TOWER LANE
STREET 2: SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404-2125
BUSINESS PHONE: 650-358-3456
MAIL ADDRESS:
STREET 1: 950 TOWER LANE
STREET 2: SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404-2125
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Blobel Friedhelm
CENTRAL INDEX KEY: 0001363213
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19825
FILM NUMBER: 17945454
MAIL ADDRESS:
STREET 1: 950 TOWER LANE, SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
4
1
certent-form4.xml
PRIMARY DOCUMENT
X0306
4
2017-06-30
0000880771
SCICLONE PHARMACEUTICALS INC
SCLN
0001363213
Blobel Friedhelm
950 TOWER LANE, SUITE 900
FOSTER CITY
CA
94404
1
1
0
0
President & CEO
Common Stock
2017-06-30
4
M
0
27654
3.55
A
149863
D
Common Stock
2017-06-30
4
S
0
27654
11
D
122209
D
Common Stock
2017-06-30
4
M
0
7390
5.13
A
129599
D
Common Stock
2017-06-30
4
S
0
7390
11
D
122209
D
Non-Qualified Stock Option (right to buy)
3.55
2017-06-30
4
M
0
27654
0
D
2020-03-05
Common Stock
27654
0
D
Non-Qualified Stock Option (right to buy)
5.13
2017-06-30
4
M
0
7390
0
D
2021-05-12
Common Stock
7390
142610
D
The reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2016.
Granted under the Issuer's 2005 Equity Incentive Plan.
25% of each shares vest one year from the date of grant, of March 5, 2010, and 2.0833% vests each month thereafter, provided that Reporting Person continues to be employed by the Issuer.
25% of such shares vest April 5, 2012 and 2.0833% vests each month thereafter, provided that Reporting Person continues to be employed by the Issuer.
/s/ Friedhelm Blobel, Ph.D.
2017-07-03